The Elusive Promise of Lenacapavir: Can a New HIV Treatment Overcome Access and Equity Gaps?

The introduction of lenacapavir, an injection-based medication, has brought renewed hope in the fight against HIV. This treatment offers an unprecedented solution to adherence issues, requiring only two shots per year compared to daily pill regimens currently in use. However, its impact will be severely limited if it fails to reach those who need it most.

In South Africa, where HIV incidence remains high, a rollout of lenacapavir began in June 2026 under an agreement between Gilead and the Global Fund. The deal promises to supply up to 2 million people with the treatment over three years at no profit. Despite this effort, concerns are mounting that it may not be enough to address the pressing need for HIV prevention in regions where access is inadequate.

Lenacapavir’s potential lies in its ease of administration. According to Salim Abdool Karim, director of the Centre for the AIDS Programme of Research in South Africa, the treatment is infinitely easier to administer than daily PrEP pills. However, those who have yet to be reached remain vulnerable to HIV transmission – adolescent girls and young women in parts of Africa, younger gay men in the West, and vulnerable communities in Eastern Europe and Central Asia.

Public-private partnerships have made lenacapavir available in some regions. However, distribution channels are patchy at best, with prices varying wildly. Doctors Without Borders’ Melissa Scharwey highlights disparities in access, pointing out that countries such as Brazil, Mexico, Peru, and Argentina have been left out of recent rollouts despite participating in clinical trials.

Even within eligible countries, vulnerable groups continue to fall through the cracks. The efficacy of lenacapavir is clear: studies suggest it can reduce HIV infections by 12-18% over a decade with targeted uptake among those at greatest risk. Monisha Sharma cautions that relying on this treatment alone may not be enough to eliminate HIV transmission.

The real challenge lies in ensuring existing treatments reach those who need them most. Lenacapavir’s success will be measured not by the number of injections administered, but by its ability to bridge the gap between those at risk and those with access to care. If lenacapavir fails to overcome these equity gaps, it risks becoming another example of a well-intentioned initiative that ultimately falls short.

The world is watching as Gilead and other stakeholders determine whether they will take the necessary steps to ensure this treatment does not become just another casualty of access and equity disparities. The question now is whether lenacapavir can overcome these challenges and live up to its promise, or if it will remain an elusive solution for those who need it most.